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a  b  s  t  r  a  c  t
Primary  myeloﬁbrosis  (PMF)  is  a clonal  hematologic  malignancy  with  a variable  disease  course;  sur-
vival  ranges  from  months  to  years.  Historically,  only  allogeneic  hematopoietic  stem  cell  transplantation
(alloHSCT)  has  demonstrated  an  ability  to alter  the  natural  history  of PMF,  but  high  treatment-related
mortality  risks  limit  the  utility  of alloHSCT  to  a  minority  of  patients  with  PMF  or myeloﬁbrosis  secondary
to  other  myeloproliferative  neoplasms.  The  recent  development  of  therapies  that  regulate  the Januseywords:
AK inhibitors
yeloﬁbrosis
roinﬂammatory cytokines
pleen volume
kinase-signal  transducer  and  activator  of  transcription  signaling  pathway  has  changed  the  treatment
landscape  from  primarily  palliative  treatment  to potential  disease  modiﬁcation.
©  2014  The  Author.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).argeted therapy
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Primary myeloﬁbrosis (PMF) is a Philadelphia chromosome-
egative myeloproliferative neoplasm (MPN) characterized by
∗ Correspondence to: Division of Hematology/Oncology, Vanderbilt University
edical Center, 2220 Pierce Avenue, 685 PRB, Nashville, TN 37232, USA.
el.: +1 615 936 3321; fax: +1 615 343 7602.
E-mail address: michael.savona@vanderbilt.edu
ttp://dx.doi.org/10.1016/j.leukres.2014.04.012
145-2126/© 2014 The Author. Published by Elsevier Ltd. This is an open access article unprogressive bone marrow ﬁbrosis resulting in increasingly inef-
fective hematopoiesis, extramedullary hematopoiesis, a variety of
inﬂammatory and vascular complications, and shortened survival.
Patients with PMF  have high circulating levels of proinﬂam-
matory cytokines believed to be responsible for constitutional
symptoms and much of the morbidity associated with the dis-
ease. Common clinical manifestations of PMF include progressive
hepatosplenomegaly, abnormal blood counts, and debilitating
symptoms such as fatigue, weight loss, night sweats, fever, pruritus,
bone pain, early satiety, abdominal pain or discomfort, arthralgias,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table  1
JAK inhibitors in development for the treatment of PMF, PPV-MF, and PET-MF.
Agent JAK(s) inhibited Phase of development Company
Pacritinib (SB1518) JAK2 III Cell Therapeutics, Inc.
Momelotinib (CYT387) JAK1, JAK2 III Gilead Sciences, Inc.
Lestaurtinib (CEP-701) JAK2 II Teva Pharmaceuticals
LY2784544 JAK2V617F II Eli Lilly and Company
AZD1480 JAK2 I/II AstraZeneca
BMS-911543 JAK2 I/II Bristol-Myers Squibb
NS-018 JAK2 I/II NS Pharma, Inc.
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to 11.2–15.4 years for low-risk disease illustrates the high variabil-
ity of the expected survival [19,21] and provides an epidemiologic
rationale for the employment of risk-based treatment strategies.
However, all 3 prognostic scoring systems have limitations, as
Table 2
DIPSS-Plus risk factors and major clinical manifestations of disease progression not
captured by DIPSS-Plus.
DIPSS-Plus risk
factors [21]
Validated laboratory
risk factors not
included in DIPSS-Plus
Clinical risk factors not
included in DIPSS-Plus
Age >65
Constitutional
symptomsa
Hemoglobin
<10 g/dL
(100 g/L)
(anemia)
RBC transfusion
dependence
WBC  count
>25 × 109/L
(leukocytosis)
Platelet count
<100 × 109/L
(thrombocyto-
penia)
Circulating blasts
(CD34+)
Unfavorable
karyotypeb
Elevated cytokines
(e.g., IL-8, IL-2R, IL-12,
and IL-15) [7]
Somatic mutations
(e.g., ASXL1)  [27]
Hypocholesterolemia
[24,25]
Marked splenomegaly
(>10 cm below left
costal margin) [24] or
increased spleen
volume [26]
MF-related symptom
burden aside from
constitutional
symptomsa
Worsening bone
marrow ﬁbrosis [22,23]
Comorbidities [23]
DIPSS, Dynamic International Prognostic Scoring System; IL, interleukin; RBC, redAK, Janus kinase; PET-MF, post-essential thrombocythemia myeloﬁbrosis; PMF, pr
yalgias, parasthesias, and even thromboembolic disease [1,2].
oth post-essential thrombocythemia (ET) myeloﬁbrosis (PET-MF)
nd post-polycythemia vera (PV) myeloﬁbrosis (PPV-MF) are phen-
typically similar to PMF, and though there may  be differential
olecular characteristics between them [3], and all 3 diseases have
 similar clinical course [4]. Consequently, most recent and ongoing
linical trials have mixed study populations of patients with PMF,
PV-MF, or PET-MF. In the absence of a clonal MPN, ﬁbrosis in the
one marrow can occur in non-neoplastic states. However, for the
ake of simplicity and for the purposes of this manuscript, PMF,
PV-MF, or PET-MF will be collectively described as myeloﬁbrosis
MF).
MF pathogenesis involves aberrant activation of the Janus
inase-signal transducer and activator of transcription (JAK-STAT)
athway, which may  result from somatic mutations directly affect-
ng JAK activity, excessive cytokine stimulation, and/or epigenetic
odiﬁcations of chromatin structure interfering with normal reg-
lation of gene expression [5–7]. The JAK2V617F gain-of-function
utation was identiﬁed several years ago and its association with
yeloproliferative phenotypes of PMF, ET, and PV is well estab-
ished [8–11]. Additional mutations within the JAK-STAT pathway
ave been identiﬁed since, and recent evidence suggests that
utations outside of the JAK-STAT pathway such as TET2 and
SXL1 also have important roles in pathogenesis [5,6]. Dysregula-
ion within the JAK-STAT pathway and epigenetic modiﬁers that
nﬂuence the JAK-STAT pathway are commonly seen in MPNs,
ut no single dominant, sufﬁcient, genetic mutation has been
dentiﬁed.
The discovery of the JAK2V617F mutation in patients with MPNs
rompted further investigation in preclinical models and eventu-
lly led to the clinical development of JAK-STAT pathway targeted
herapy for PMF. Several JAK inhibitors are currently in devel-
pment (Table 1), and one agent, the oral JAK1/JAK2 inhibitor
uxolitinib, has been approved for patients with intermediate-1,
ntermediate-2, or high-risk PMF, PPV-MF, or PET-MF. In 2 phase III
linical trials in patients with intermediate-2 or high-risk MF,  rux-
litinib has been shown to signiﬁcantly reduce spleen volume and
o alleviate MF-related symptoms compared with placebo or best
vailable therapy (BAT) [12,13]. These advantages translated into
linically important improvements in quality of life (QOL) measures
13–15], and long-term follow-up data from the 2 studies suggest
hat ruxolitinib prolongs overall survival versus both placebo and
AT in patients with MF  [16,17].
Aside from allogeneic hematopoietic stem cell transplantation
alloHSCT), previously used therapies for PMF  have been palliative,
ith only limited beneﬁts in QOL and symptom management. Until
ecently, the only treatment with a clearly demonstrated impact
n disease progression has been alloHSCT, but treatment-related
ortality is high and only a minority of patients qualify for thisntensive therapy [18]. New agents have the potential to alter the
atural history and make a long-term impact on the disease. The
im of this article is to explore current evidence that new rationally
esigned therapy may  alter the natural history of MF. myeloﬁbrosis; PPV-MF, post-polycythemia vera myeloﬁbrosis.
2. Markers of disease progression and incompleteness of
prognostic scoring systems
The prognosis of PMF  is variable. Risk stratiﬁcation with the
International Prognostic Scoring System (IPSS) [19], the Dynamic
IPSS (DIPSS) [20], or the DIPSS-Plus [21] has helped clinicians to
assign risk and determine appropriate candidates for alloHSCT.
Each scoring system incorporates assorted patient risk factors for
survival in predictive models based on multiparametric regression
analyses. Important disease characteristics predictive of poor sur-
vival that are included in all of these scoring systems are age of >65
years, presence of constitutional symptoms (weight loss >10% of the
baseline value in the year preceding diagnosis and/or unexplained
fever or excessive sweats persisting for >1 month), hemoglobin
<10 g/dL (100 g/L), leukocyte (white blood cell) count >25 × 109/L,
and circulating blasts ≥1% [19–21]. In addition, DIPSS-Plus includes
unfavorable karyotype, platelet count <100 × 109/L, and red blood
cell transfusion dependence (Table 2 [7,21–27]), each of which is
a negative prognostic factor for survival [21]. The fact that sur-
vival estimates range from 1.3 to 2.2 years for high-risk diseaseblood cell; WBC, white blood cell.
a Weight loss >10% of the baseline value in the year preceding diagnosis and/or
unexplained fever or excessive sweats persisting for more than 1 month.
b Complex karyotype or sole or 2 abnormalities that include +8, −7/7q−, i(17q),
−5/5q−,  12p−, inv(3), or 11q23 rearrangement.
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ach lacks the capacity to deﬁne the effects of profound ﬁbrosis,
eutropenia, massive hepatosplenomegaly, elevated cytokines or
igniﬁcant coagulopathy—all of which are clinical manifestations
f advanced disease, which may  or may  not accompany high-risk
eatures traditionally measured with DIPSS. Likewise, while the
inetics of genetic evolution and molecular features have intuitive
tility in assessing risk, few have been validated as harbingers of
oor survival.
Some of the most common manifestations of clinical pro-
ression of MF  are worsening splenomegaly and an increase in
ymptom severity. However, current prognostic scoring systems
19–21] do not consider the effects of splenomegaly and include
nly a narrowly deﬁned set of constitutional symptoms consist-
ng of unexplained fever, weight loss, and persistent night sweats
Table 2). Thus, the prognostic impact of spleen-related symp-
oms such as abdominal discomfort, left subcostal pain, and early
atiety, and most non-spleen-related symptoms, including itch-
ng, bone or muscle pain, fatigue, dyspnea, and insomnia are not
easured in this context. The worsening splenomegaly and rapid
ymptomatic deterioration observed in patients who participated
n the COntrolled MyeloFibrosis study with ORal JAK inhibitor
reatment (COMFORT) trials and did not receive ruxolitinib [12,13]
llustrate the signiﬁcant risk of clinical progression in patients with
ntermediate-2 or high-risk MF  and the inadequacy of manage-
ent approaches based on “watchful waiting” or BAT, which are
nable to provide durable symptomatic relief and/or improvement
f splenomegaly. The symptom burden has a profoundly negative
mpact on patients’ QOL [28], and the presence of constitutional
ymptoms beyond what is captured in current validated scoring
ystems [19] may  have a negative effect on survival.
Long-term sequelae related to splenomegaly that impact sur-
ival include poor nutritional status, cachexia, and low cholesterol
24,25], and in select patients evidence of hypersplenism and
hrombohemorrhagic complications [19]. In some patients, MF
ventually transforms to acute myeloid leukemia, which is char-
cterized by particularly poor response to therapy, with a reported
edian survival of less than 3 months [29]. Cervantes et al. char-
cterized the causes of death for a relatively large cohort of 517
atients who died from complications of the disease [19]. Their
nalysis revealed that nearly one-third (31%) of the patients for
hom the cause of death was known (n = 276) succumbed to
omplications of acute myeloid leukemia. Other common causes
f death included progression of disease without transformation
18%), thrombosis and cardiovascular complications (13%), and
nfection (11%) [19]. Patients with MF  may  develop any and all of
hese complications during a lifetime. It is hoped, and likely, that
ecreasing the incidence of each of these speciﬁc causes of death
n these patients will positively affect survival and QOL. Is it possi-
le, then, to alter the natural history of this complex disease with
brogation of some, or all, of these complications with rationally
esigned therapy?
. Aberrant activation of the JAK-STAT pathway
The JAK family of cytoplasmic tyrosine kinases has 4 identi-
ed members: JAK1, JAK2, JAK3, and TYK2 [30–33]. The JAK-STAT
athway is involved in the regulation of cell growth, survival, and
evelopment, and it has an essential role in normal hematopoiesis
34,35]. Binding of cytokines and hematopoietic growth factors
o their cognate transmembrane receptors leads to phosphoryla-
ion and activation of JAK tyrosine kinases in the cytoplasm, which
hen phosphorylate the cytoplasmic domains of the receptors [36].
eceptor phosphorylation ultimately leads to the activation of
TATs. The activated STATs dimerize and translocate to the nucleus
o regulate transcription [37,38].ch 38 (2014) 1004–1012
The pathogenesis is complex (Fig. 1 [5,6,39,40]). Overactivity of
the JAK-STAT pathway may  occur because of increased proinﬂam-
matory cytokine stimulation of JAK1 and JAK2, somatic mutations
affecting components of the JAK-STAT signaling cascade, and/or
mutations in genes encoding epigenetic modiﬁers [5–7]. As men-
tioned, the dysregulation of the JAK-STAT pathway is complex with
many potential types of aberrancy. From a therapeutic standpoint,
this contrasts starkly with BCR-ABL1, the dominant rogue kinase
in chronic myeloid leukemia, which has been successfully targeted
with direct BCR-ABL1 inhibitors, leading to quiescent disease for
most adherent patients. In MF,  somatic mutations in the JAK-STAT
pathway of hematopoietic stem cells result in dysregulation of nor-
mal  physiologic signaling. Nearly half of all patients with PMF have
no identiﬁable JAK mutation [6]. Perhaps, clonal evolution and the
development of consequent mutations lead to the disease pheno-
type [41]. Furthermore, the disease-initiating stem cell mutation
remains unknown and is unlikely to be associated with JAK2 [42].
Thus, JAK inhibition does not silence a dominant driving geno-
type, but rather affects an aberrantly active signaling pathway and
reduces the inﬂammatory, proliferative phenotype associated with
its aberrancy.
The JAK2V617F activating mutation was  discovered in patients
with MPNs in 2005 [8–11]. This mutation is not only present
in ∼50–60% of patients with PMF, but also in ∼60% of patients
with ET and in >95% of patients with PV [43]. It results in con-
stitutive activity of JAK2, which leads to excessive production
of proinﬂammatory cytokines and transcription of cell survival-
promoting molecules and anti-apoptotic molecules. The JAK-STAT
pathway also may  be overactive in patients who  do not harbor
the JAK2V617F mutation. For example, mutations in JAK2 exon 12
and the myeloproliferative leukemia virus proto-oncogene (MPL)
encoding the thrombopoietin receptor, as well as in KIT, CBL, and
TET2, have been consistently identiﬁed in patients with MPNs
[2]. Recent analyses showed that most patients without a JAK2 or
MPL mutation harbor mutually exclusive mutations in the calreti-
culin gene (CALR),  and cells expressing these mutations in CALR
were sensitive to JAK2 inhibition [39,44]. In addition, patients
without the JAK2V617F mutation have shown clinical responses
to JAK inhibitor therapy [12], including individual patients with
CALR mutations [45]. Altered gene expression as a result of epi-
genetic dysregulation in MPNs also may  affect genes that play a
role in cell survival, differentiation, and/or proliferation, includ-
ing those encoding calcitonin A, ABL1, SFRP2,  WIF-1, SOCS1,  SOCS3,
CXCR4, and RARˇ2 [5]. For example, ASXL1 mutations have been
associated with epigenetic dysregulation resulting in the loss
of transcriptional repression of leukemogenic genes and in the
silencing of tumor suppressor genes [46]. Thus, aberrant expres-
sion of numerous genes may contribute to the pathogenesis of
PMF, regardless of the presence or absence of the JAK2V617F
mutation.
4. JAK inhibition: treatment responses and effect on
survival
Studies of JAK inhibition have shown beneﬁts with regard to
spleen volume, MF-related symptoms, QOL, body weight, choles-
terol levels, biomarkers and histopathology, and overall survival.
4.1. Spleen volume
The durability of spleen volume reductions with ruxolitinib
treatment in patients with intermediate-2 or high-risk MF  has
now been demonstrated by long-term follow-up data from both
COMFORT-I and COMFORT-II. In COMFORT-I, almost two-thirds of
the patients who  achieved a ≥35% reduction in spleen volume from
M.R. Savona / Leukemia Research 38 (2014) 1004–1012 1007
Fig. 1. Primary myeloﬁbrosis (PMF) pathogenesis. Common overexpression of Janus kinase 2 (JAK2) may  result in additive activation of the Janus kinase-signal transducer
and  activator of transcription (JAK2-STAT) pathway by facilitating increased cell surface expression of hematopoietic growth factor receptors. Somatic mutations in the
thrombopoietin (TPO) receptor gene MPL  or in JAK2 (i.e., JAK2V617F) result in constitutive activation of the JAK-STAT pathway in hematopoietic stem cells. JAK2V617F may
cause epigenetic dysregulation by preventing histone H2A and H4 methylation through inactivation of protein arginine methyl transferase 5 or by decreasing chromatin-
binding of HP1, a repressor of heterochromatin activity. Other epigenetic mutations associated with PMF, which may  occur antecedent or precedent to the acquisition of the
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sAK2V617  mutation [40], may  affect the status of DNA methylation (TET2), histone H
ranscriptional activity [5,6]. CALR mutations, which are mutually exclusive with JA
ave  been associated with cytokine-independent STAT5 activation [39].
aseline maintained this level of reduction for at least 2 years
16], and the probability of maintaining this response for >132
eeks was 53% [47]. Durable reductions in spleen volume also
ere observed in long-term analyses of data from COMFORT-II
17]. Treatment of patients with intermediate- or high-risk MF  with
he JAK1/2 inhibitor momelotinib (CYT387) for up to 2.5 years in
 phase I/II trial resulted in durable reductions in palpable spleen
ize of ≥50% in more than half of the eligible patients, with a max-
mal response duration of almost 2 years [48]. Data from studies
f other JAK inhibitors have thus far shorter periods of follow-up.
onetheless, they also demonstrate the efﬁcacy of JAK inhibition
n improving splenomegaly. In a phase II trial, treatment with the
AK2 inhibitor pacritinib provided a ≥35% reduction in spleen vol-
me  at week 24 from baseline in 32% of patients with MF,  and at the
ime of the report, the median duration of response had not been
eached [49]. Similarly, considerable reductions in splenomegaly
ave been seen in early phase clinical trials with the JAK2 inhibitors
edratinib (SAR302503/TG101348) [50,51] and lestaurtinib [52],
nd with LY2784544 [53,54], a selective JAK2V617F inhibitor. In
 phase II study of fedratinib, 30–64% of patients with MF  achieved
 ≥35% reduction in spleen volume after three 28-day cycles of
herapy, illustrating the speed of considerable spleen size reduc-
ion [50]. (Unfortunately, clinical development of fedranitib was
iscontinued because of safety concerns prompted by reports of
ases of Wernicke’s encephalopathy [55].)
.2. Myeloﬁbrosis-related symptoms and quality of lifeJAK inhibition improves MF-related symptoms, which seems to
mprove QOL. Ruxolitinib treatment has been shown to improve MF
ymptoms and QOL measures compared with both placebo and BATylation (EZH2), or chemical histone modiﬁcation (ASXL1), resulting in dysregulated
d MPL mutations, appear to be early events in PMF  pathogenesis, and, on occasion,
[12,13]. In addition, spleen volume reductions were correlated with
improvements in MF  symptoms and QOL in COMFORT-I [14]. In the
phase I trial of momelotinib, most treated patients experienced an
improvement in constitutional symptoms [48]. Pacritinib therapy
was associated with signiﬁcant reductions in MF  symptoms at 6
months, which included abdominal pain, bone pain, early satiety,
worst fatigue, inactivity, night sweats, and pruritus [49]. The clini-
cal experience with fedratinib also is marked with improvement or
resolution of early satiety, fatigue, night sweats, itching, abdominal
pain, and abdominal discomfort [50,51]. Reductions of symptom
burden with LY2784544 were seen within the ﬁrst 2 treatment
cycles and included improvements in key MPN-related symptoms,
fatigue/enjoyment of life, fatigue/walking ability, itching, early sati-
ety, inactivity, bone pain, and night sweats [53]. At 12 weeks, a ≥50%
reduction in total symptom burden was observed in 56% of patients
[54].
4.3. Body weight and metabolic status
Cachexia is a common manifestation of disease progression, and
unwanted weight loss has been established as a negative prognostic
factor [19,24]. Cachexia in patients with MF  likely is related to the
excessive production of cytokines such as interleukin 6 (IL-6) and
tumor necrosis factor alpha (TNF-), which are elevated in these
patients [56]. Elevated blood levels of IL-6, which signals through
the JAK-STAT pathway, have been associated with cancer-related
cachexia in clinical studies [57,58], and TNF- infusion recently
has been shown to promote muscle protein loss and increased
IL-6 release in healthy individuals [59]. In COMFORT-I, ruxolitinib
treatment was associated with increases in body weight and total
cholesterol from baseline, whereas both parameters decreased over
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ime in patients who received placebo [60]. Speciﬁc effects of JAK
nhibition on cachexia are not well illustrated, but improvement of
ppetite and metabolic status are strongly correlated with spleen
ize reduction. Changes in body weight or total cholesterol with JAK
nhibitors other than ruxolitinib have not been reported to date.
.4. Biomarkers of inﬂammation
Chronically elevated levels of proinﬂammatory cytokines have
een implicated in the pathogenesis of bone marrow ﬁbrosis [61] as
ell as in the mediation of noxious effects underlying the compro-
ised metabolic/nutritional status in affected patients [7,12,56]. In
ddition, the circulating levels of some cytokines, including IL-8, IL-
R, IL-12, and IL-15, have been shown to be independent prognostic
actors of survival in patients with MF,  which suggests a possi-
le role in disease progression [7]. Because these cytokines may
upport the tumor microenvironment through autocrine signaling
hat promotes tumor cell survival and proliferation, it is reason-
ble to hypothesize that the normalization of circulating cytokine
evels may  alter the trajectory of disease evolution. Rapid reduc-
ions in plasma levels of proinﬂammatory cytokines have been
bserved in response to ruxolitinib (IL-8, IL-6, and TNF-) [12,56]
nd fedratinib (TNF-,  IL-1RA, and IL-18) [50]. Given the associ-
tion between elevated cytokine expression and survival [7], this
ecrease in inﬂammatory biomarkers is propitious.
.5. Bone marrow ﬁbrosis
Bone marrow ﬁbrosis is variable and typically graded by the
ensity of reticulin and collagen ﬁbers in marrow replacement
62]. In PMF, marrow ﬁbrosis is usually progressive and there is
ncreasing evidence that bone marrow ﬁbrosis grade has prognostic
igniﬁcance [22,23]. Marrow ﬁbrosis may  resolve spontaneously
n rare cases [63,64] or with alloHSCT [65] and may  respond to
reatment with interferon-alpha (IFN-) in select patients [66].
therwise, reversal of marrow ﬁbrosis has not been seen with tradi-
ional therapies. However, a post hoc analysis from the ruxolitinib
hase I/II study suggests that JAK inhibition may  be able to slow
he progression of bone marrow ﬁbrosis in some patients [67,68].
one marrow biopsies from patients treated with ruxolitinib in
 single institution phase I/II study were matched to historical
ontrol bone marrow biopsies from patients who received BAT in
urope at corresponding time points. At 5 years of follow-up, 35%
f ruxolitinib-treated compared with 3% of BAT-treated patients
howed improvement in bone marrow ﬁbrosis grade. Furthermore,
he odds for worsening bone ﬁbrosis were signiﬁcantly greater with
AT (76%; n = 29) than ruxolitinib (26%; n = 23) [68]. Consistent with
he notion that JAK inhibition improve bone marrow ﬁbrosis [69],
ata from the phase I study of LY2784544 showed that after 5 cycles
f therapy, bone marrow ﬁbrosis grade was reduced in 3 of 5 MF
atients analyzed [53].
Although encouraging, the improvement in bone marrow
brosis observed in patients receiving JAK inhibitors generally
ccurred slowly and overall was modest. For many patients, lasting
mprovement of bone marrow function may  require a multifaceted
pproach beyond the use of JAK inhibitors. In the future, this
pproach may  include the use of epigenetic modiﬁers such as
he histone deacetylase (HDAC) inhibitor panobinostat [70,71],
r antiﬁbrotic agents such as PRM-151 (recombinant human
entraxin-2) [72] and a monoclonal antibody against LOXL-2 [73].
hese agents will be discussed in more detail in Section 5..6. Overall survival
Follow-up data from COMFORT-I and COMFORT-II suggest that
uxolitinib therapy was associated with a survival advantagech 38 (2014) 1004–1012
compared with both placebo and BAT [16,17]. These analyses were
based on randomized treatment allocation at the beginning of the
studies, and the control arms included patients who  crossed over to
ruxolitinib treatment after meeting prespeciﬁed conditions of dis-
ease progression. In COMFORT-I, all patients randomized to placebo
had discontinued or were receiving ruxolitinib within 3 months
after the primary analysis [16]. The short exposure to placebo
taken together with the growing exposure to ruxolitinib treatment
in the placebo group has made interpretation of survival bene-
ﬁts difﬁcult [47]. Exploratory statistical analyses suggest that the
diminished survival disadvantage of the placebo arm (compared
with the ruxolitinib arm) at 3 versus 2 years follow-up may  be a
direct result of the crossover to ruxolitinib in this treatment arm
[47]. A corresponding effect was  not observed in COMFORT-II [17],
likely because of delayed crossover from BAT to ruxolitinib con-
sequent to differences in crossover rules between the COMFORT
studies. Nonetheless, depending on the time of analysis, patients
randomized to ruxolitinib generally had a distinct survival advan-
tage of 30–50% compared with those randomized to placebo [12,16]
or BAT [17]. Consistent with these ﬁndings, a comparison of sur-
vival data from patients with PMF  from the COMFORT-II study
with those from a matched control population of the DIPSS study
[74] revealed a 36% reduction in the risk of death with ruxolitinib
versus conventional therapy (HR = 0.64; 95% conﬁdence interval:
0.4–0.96; P = 0.034). Additional analyses showed that the use of
ruxolitinib doubled the 8-year survival probability at diagnosis
from 15.9% to 32.2%. Together, these data suggest that ruxolitinib
may  affect disease progression and alter the natural history of the
disease.
5. Rational approaches to modiﬁcation of disease beyond
JAK inhibition
In addition to the investigational JAK inhibitors, agents targeted
to other signaling pathways or to epigenetic modiﬁers are in various
stages of clinical development for the treatment of MPN-associated
MF.  They include HDAC inhibitors and immunomodulatory drugs.
In addition, the antiﬁbrotic monoclonal antibodies fresolimumab
and GS-6624, recombinant PTX-2, and the telomerase inhibitor
imetelstat (GRN163L) may  have potential roles in treatment as sin-
gle agents or in combination therapy. Recently, encouraging results
were obtained in a single-center study of imetelstat in patients with
intermediate-2 or high-risk MF.  Of 18 patients followed for at least
3 months, 8 (44%) had an overall response, including 4 patients with
complete remission, as evidenced by the reversal of BM ﬁbrosis and
recovery of normal megakaryocyte morphology, and 1 patient with
partial remission [75].
In addition to imetelstat, approaches complementary to JAK
inhibitor therapy to reverse bone marrow ﬁbrosis or retard its
progression are being explored. The human monoclonal antibody
fresolimumab antagonizes transforming growth factor beta (TGF),
a mediator of bone marrow ﬁbrosis in thrombopoietin-induced MF
[76,77], and it has been safely administered to patients with focal
segmental glomerulosclerosis [78]. Likewise, a monoclonal anti-
body (GS6624, AB0023) targeting lysyl oxidase-like 2 (LOXL-2), a
protein active in the remodeling of extracellular matrix architec-
ture in pathologic ﬁbrosis, has been shown to reduce TGF pathway
signaling and ﬁbroblast activation in murine models of ﬁbrosis [73].
A phase II study of the anti-LOXL-2 antibody GS6624 as monother-
apy or in combination with ruxolitinib is underway in patients with
MF.  PRM-151 (recombinant human serum amyloid P/pentraxin 2),
an antiﬁbrotic protein, has recently been shown in an initial phase
I study to be well tolerated and to reduce ﬁbrocyte numbers by
30–50% in patients with pulmonary ﬁbrosis [79]. Investigation in
patients with MF  is underway.
M.R. Savona / Leukemia Research 38 (2014) 1004–1012 1009
Fig. 2. Theoretical changes in hematopoietic potential with treatment of primary myeloﬁbrosis (PMF) with rationally designed therapy. Hematopoietic function declines
normally with age (gray dotted line), but under normal circumstances this does not contribute to mortality. Patients with PMF  have shortened overall survival associated
with  progressive decline in normal hematopoiesis (red line), but therapeutic intervention may  diminish progression of disease (green lines) to normal physiologic conditions
o s (gre
r seque
l
s
s
t
s
s
1
o
3
a
c
m
c
p
m
p
i
m
p
r
a
u
T
c
6
m
w
a
b
r
m
p
m
l
mr  even lead to the resumption of hematopoiesis expected in age-matched control
ational therapies will delay the accumulation of high-risk genetic lesions and con
egend,  the reader is referred to the web version of this article.)
Panobinostat (LBH589) is a pan-HDAC inhibitor that was
hown in a phase I trial to achieve a 100% reduction in palpable
plenomegaly in 3 of 5 patients who received at least 6 cycles of
reatment and were evaluable for response; the other 2 patients had
table disease [80]. One of the 3 patients who had 100% reduction in
plenomegaly demonstrated bone marrow ﬁbrosis resolution after
6 cycles [80]. In a phase II trial of 22 patients with intermediate-
r high-risk MF,  the HDAC inhibitor pracinostat achieved a median
-cm reduction in splenomegaly in 6 (27%) patients [81]. These
nd other targeted agents may  be most effective when given in
ombination with JAK inhibitors to maximize blockade of disease
echanisms, and studies of combination therapy with rational
ombinations of these targeted agents are underway. In a recent
hase I study, prolonged therapy with panobinostat elicited dra-
atic reversal of bone marrow histopathologic abnormalities in 2
atients [80]. A combination study of panobinostat and ruxolitinib
n patients with MF  is ongoing.
The use of IFN- may  lead to spleen size and symptom improve-
ent as well as reduction in marrow ﬁbrosis in some patients,
articularly those with early-stage disease [66]. However, as a
ecent analysis of studies of IFN- shows, widely variable responses
mong different groups of MF  patients have been reported, and the
se of IFN- in more advanced disease is not recommended [82].
he value of IFN- for certain subgroups of patients with MF  or in
ombination with JAK inhibitors has yet to be demonstrated.
. JAK inhibition and changing the natural history of
yeloﬁbrosis
Development of therapy that regulates the JAK-STAT path-
ay represents an important step forward toward therapy that
lters the natural history of the disease. Although the most salient
eneﬁts are the alleviation of splenomegaly and non-spleen-
elated symptoms, concomitant with an improvement in QOL
easures [12,13], there is compelling evidence that these thera-
ies may  improve the prognosis of these patients [16,17,83]. The
itigation of cachexia-associated risk factors, including weight
oss [19,60], hypocholesterolemia [24,25,60], and elevated inﬂam-
atory cytokines [7,12,56] likely contributes to the apparenten dotted line). It is hoped that future efforts tailored to earlier intervention with
nt clinical progression. (For interpretation of the references to color in this ﬁgure
improved survival seen with the use of ruxolitinib. Moreover, at
least in some patients treated with these new agents, progres-
sion of ﬁbrosis may  be retarded or relent [68,69,75]. With our
current understanding, worsening marrow ﬁbrosis, while clearly
associated with cytopenias and ineffective hematopoiesis, has not
been deﬁnitively linked with a decline in overall survival. More-
over, although most patients with marrow ﬁbrosis improvements
had corresponding improvements in symptoms and spleen size in
observational studies, changes in marrow ﬁbrosis do not always
parallel spleen size reduction or relief of disease-related symp-
toms [66,68]. In addition, the rapid clinical improvements seen in
the COMFORT-II study were not accompanied by or dependent on
major changes in marrow histomorphology [13].
This raises the intriguing possibility that new therapies delay
disease progression, including symptom onset in asymptomatic
patients. A thorough assessment of the beneﬁts and risks of these
agents for lower-risk patients may  require further exploration in
clinical trials. Intervention in early stages of PMF  with targeted ther-
apies capable of changing the disease trajectory (Fig. 2) may lead
to better outcomes, including longer survival and increased QOL.
Because of the inherent clinical and genetic heterogeneity of the
disease, individualized risk assessment may  be helpful in predicting
the disease course of individual patients more accurately. It is con-
ceivable that speciﬁc patterns of inﬂammatory cytokine expression
or gene expression signatures may  be used in the future to identify
patients who are at risk of more rapid deterioration and therefore
would be candidates for earlier intervention. Elevated expression
of IL-8 in the serum, which appears to be secondary to increased
expression of nuclear factor eythroid-2 [84], has been identiﬁed
as an independent risk factor for shortened survival in PMF  [7],
and serum levels may  revert to normal values in both JAK2V617F-
positive and -negative patients in response to JAK inhibitor therapy
[56]. JAK inhibitors have shown to be effective in patients with and
without the JAK2V617F mutation [12,85].
There are conﬂicting arguments as to the extent by which
JAK2V617F allele burden correlates with disease severity in ET,
PV and MF  [86–88], but the general consensus is that allele bur-
den is higher in more severe disease, at least in the case of ET.
Furthermore, low allele burden at baseline was associated with
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mproved treatment response to IFN- in patients with PV or ET
89], whereas allele burden >1% shortly after alloHSCT was asso-
iated with increased risk of relapse and poorer overall survival
90]. JAK2V617F allele burden, which can be measured reliably
rom either peripheral blood or bone marrow biopsies [91] may
rove useful and convenient in some clinical settings, such as esti-
ating the risks of myeloﬁbrotic transformation or thrombosis in
atients with ET or PV [92]. However, JAK2V617F allele burden has
ot yet proven useful as a prognostic marker or harbinger of clinical
esponses to JAK inhibitors [85,93].
. Conclusions
With the exception of alloHSCT, and perhaps IFN- in a select
roup of patients, conventional therapies do not impact the natural
istory of PMF  in any appreciable way. Considering the successes
chieved with therapy targeting the JAK-STAT pathway and the
romising results achieved in early trials with other therapies tar-
eted to pathogenic mechanisms of PMF, the treatment strategies
nd expectations are changing. Major advances in the treatment
ave been realized with the introduction of JAK inhibitors, and
ow a more versatile armamentarium is needed, given both the
eterogeneity of the disease and the diversity of risk factors.
ntiﬁbrotic agents, immunomodulators, and epigenetic modiﬁers,
hich are currently in clinical trials, are plausible candidates as
onotherapy or in combination with JAK inhibitors. It is hoped
hat earlier identiﬁcation of patients with poor prognosis, together
ith more options for disease-modifying therapy, will eventually
ead to greater improvements in survival in a greater number of
atients.
A growing sentiment that the new rational therapies may
hange the natural history of the disease is reﬂected in the
ew consensus recommendations by the International Working
roup-Myeloproliferative Neoplasms Research and Treatment and
uropean LeukemiaNet [94]. In addition to specifying the clin-
cal and hematologic criteria for clinical improvement, anemia
esponse, spleen response, and symptom response, the consen-
us recommendations provide rigorous deﬁnitions for complete
nd partial remission based on cytogenetic and molecular response
94]. With the accumulation of evidence indicating the potential for
argeted agents to modify the disease course, there is new optimism
hat the goal of obtaining a complete response with drug therapy
n an increasing number of patients is within reach. Disease activ-
ty in these patients is manifested by a variety of symptoms and
etabolic derangements that seem to improve with JAK inhibition.
n a progressive catabolic state such as PMF, sustained mitigation
f these clinical characteristics seems to lead to improved survival,
onsistent with the notion that the trajectory of the natural history
n these patients has changed.
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